NCT00246753 - Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

July 31, 2012

Study Completion Date

May 31, 2013

Conditions

Prostate Cancer

Interventions

DRUG

lapatinib ditosylate

1500 mg, daily until disease progression

Trial Locations (3)

Rex Cancer Center at Rex Hospital, Raleigh

Duke Comprehensive Cancer Center, Durham

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill